Logo image of GALT

GALECTIN THERAPEUTICS INC (GALT) Stock Fundamental Analysis

NASDAQ:GALT - Nasdaq - US3632252025 - Common Stock

1.23  -0.01 (-0.81%)

Premarket: 1.22 -0.01 (-0.81%)

Fundamental Rating

0

GALT gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of GALT have multiple concerns. GALT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GALT has reported negative net income.
In the past year GALT has reported a negative cash flow from operations.
In the past 5 years GALT always reported negative net income.
GALT had a negative operating cash flow in each of the past 5 years.
GALT Yearly Net Income VS EBIT VS OCF VS FCFGALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -156.12%, GALT is doing worse than 85.66% of the companies in the same industry.
Industry RankSector Rank
ROA -156.12%
ROE N/A
ROIC N/A
ROA(3y)-138.28%
ROA(5y)-107.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GALT Yearly ROA, ROE, ROICGALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

GALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GALT Yearly Profit, Operating, Gross MarginsGALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

GALT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GALT has more shares outstanding
Compared to 1 year ago, GALT has a worse debt to assets ratio.
GALT Yearly Shares OutstandingGALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
GALT Yearly Total Debt VS Total AssetsGALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -22.81, we must say that GALT is in the distress zone and has some risk of bankruptcy.
GALT's Altman-Z score of -22.81 is on the low side compared to the rest of the industry. GALT is outperformed by 88.32% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.81
ROIC/WACCN/A
WACCN/A
GALT Yearly LT Debt VS Equity VS FCFGALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 1.13 indicates that GALT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.13, GALT is doing worse than 86.37% of the companies in the same industry.
GALT has a Quick Ratio of 1.13. This is a normal value and indicates that GALT is financially healthy and should not expect problems in meeting its short term obligations.
GALT has a worse Quick ratio (1.13) than 84.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
GALT Yearly Current Assets VS Current LiabilitesGALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.95% over the past year.
EPS 1Y (TTM)3.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GALT will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.57% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.62%
EPS Next 2Y-50.81%
EPS Next 3Y-15.57%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GALT Yearly Revenue VS EstimatesGALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
GALT Yearly EPS VS EstimatesGALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GALT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GALT Price Earnings VS Forward Price EarningsGALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GALT Per share dataGALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

GALT's earnings are expected to decrease with -15.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.81%
EPS Next 3Y-15.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTIN THERAPEUTICS INC

NASDAQ:GALT (1/21/2025, 8:02:38 PM)

Premarket: 1.22 -0.01 (-0.81%)

1.23

-0.01 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners15.34%
Inst Owner Change0.44%
Ins Owners21.36%
Ins Owner Change0.4%
Market Cap76.64M
Analysts43.33
Price Target11.22 (812.2%)
Short Float %18.76%
Short Ratio9.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.39%
Min EPS beat(2)-22.55%
Max EPS beat(2)11.76%
EPS beat(4)2
Avg EPS beat(4)-6.31%
Min EPS beat(4)-22.55%
Max EPS beat(4)11.76%
EPS beat(8)4
Avg EPS beat(8)-4.36%
EPS beat(12)7
Avg EPS beat(12)2.75%
EPS beat(16)11
Avg EPS beat(16)8.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)7.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS-1.48
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -156.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-138.28%
ROA(5y)-107.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -22.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y-0.62%
EPS Next 2Y-50.81%
EPS Next 3Y-15.57%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.46%
OCF growth 3YN/A
OCF growth 5YN/A